ROIV Bathi saben saham sajrone rolas wulan pungkasan Roivant

Logo korporat perusahaan Roivant Corp (ROIV)

Geopolitical risks are complicating international trials and patent protection for Roivant Sciences Ltd. (ROIV). The trailing 12-month EPS shows that the metric has reached -0.56. The decentralized hub effectively revitalizes neglected drugs, creating an innovative pipeline. High liquidity following asset divestitures and share buybacks establish a strong fundamental basis for growth.

ROIV (Roivant Corp) riwayat Bathi saben saham sajrone 12 wulan pungkasan saka 04.07.2022 nganti 17.11.2026

Rincian metrik keuangan lan pasar Roivant Sciences Ltd (ROIV)

- kuotasi saiki lan rata-rata prakiraan nilai:
Analisis komprehensif perusahaan:ROIV - Roivant Sciences
Produk seri Roivant

Roivant Sciences Ltd. (ROIV) optimizes business capital intensity through a decentralized biotech asset management structure and the minimization of direct operating expenses. This rolling trailing twelve-month earnings per share snapshot aggregates net income over the last year, enabling an assessment of the actual efficiency of EPS recovery following market shocks and identifying the risk of overpaying for a temporary price bounce of the issuer.